Vectura said yesterday that the FDA approved an Investigational New Device application for its drug-device combination to treat asthma in children 12 months to 8 years old. The UK-based company’s device, VR647, uses the Akita Jet nebulizer for the delivery of nebulized budesonide.
Vectura’s drug-device combination product provides faster delivery time and better lung deposition of budesonide, according to the company, and enables a patient to potentially lower their dosage while maintaining efficacy.
DeviceTalks Minnesota's leadership track is designed to provide attendees with insights on topics such as:
Use code SAVE15 to save 15%!